Renovaro IncNASDAQ:RENBNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7564
- TODAY'S CHANGE (%)0.1461 (23.9390%)
- Bid / Lots0.7564/ 1
- Ask / Lots0.7689/ 6
- Open / Previous Close0.6500 / 0.6103
- Day Range
- 52 Week Range
- Volume897,310
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RENB |
|---|---|---|
| 09:32 ET | 26775 | 0.689999 |
| 09:33 ET | 6989 | 0.67 |
| 09:35 ET | 56692 | 0.6922 |
| 09:37 ET | 4282 | 0.726676 |
| 09:39 ET | 289 | 0.700001 |
| 09:42 ET | 11324 | 0.736368 |
| 09:44 ET | 415 | 0.7 |
| 09:46 ET | 1200 | 0.7373 |
| 09:50 ET | 1226 | 0.75 |
| 09:51 ET | 15725 | 0.777126 |
| 09:53 ET | 20286 | 0.81 |
| 09:55 ET | 55993 | 0.72 |
| 09:57 ET | 19061 | 0.777 |
| 10:00 ET | 11479 | 0.76 |
| 10:02 ET | 11844 | 0.765 |
| 10:04 ET | 2738 | 0.7625 |
| 10:06 ET | 63670 | 0.72041 |
| 10:08 ET | 4283 | 0.7457 |
| 10:09 ET | 1440 | 0.7375 |
| 10:11 ET | 2401 | 0.7547 |
| 10:13 ET | 2053 | 0.74999 |
| 10:15 ET | 50633 | 0.759999 |
| 10:18 ET | 12281 | 0.83145 |
| 10:20 ET | 31766 | 0.7926 |
| 10:22 ET | 18395 | 0.776 |
| 10:24 ET | 23087 | 0.7548 |
| 10:26 ET | 24206 | 0.784999 |
| 10:27 ET | 2139 | 0.779699 |
| 10:29 ET | 200 | 0.7797 |
| 10:31 ET | 1400 | 0.7797 |
| 10:36 ET | 5032 | 0.7547 |
| 10:38 ET | 400 | 0.7548 |
| 10:40 ET | 100 | 0.7797 |
| 10:42 ET | 5177 | 0.7501 |
| 10:44 ET | 19554 | 0.7347 |
| 10:45 ET | 76018 | 0.73 |
| 10:47 ET | 1818 | 0.74 |
| 10:49 ET | 5643 | 0.73 |
| 10:51 ET | 10607 | 0.7728 |
| 10:54 ET | 2300 | 0.789779 |
| 10:56 ET | 23124 | 0.753714 |
| 10:58 ET | 11016 | 0.7603 |
| 11:00 ET | 6571 | 0.7547 |
| 11:02 ET | 1600 | 0.7677 |
| 11:03 ET | 16845 | 0.75 |
| 11:05 ET | 8900 | 0.7653 |
| 11:07 ET | 300 | 0.76931 |
| 11:09 ET | 7057 | 0.745801 |
| 11:12 ET | 113 | 0.755451 |
| 11:14 ET | 8838 | 0.759 |
| 11:16 ET | 2266 | 0.755 |
| 11:18 ET | 100 | 0.7789 |
| 11:20 ET | 3586 | 0.755 |
| 11:21 ET | 4795 | 0.755 |
| 11:25 ET | 200 | 0.7547 |
| 11:27 ET | 300 | 0.7547 |
| 11:30 ET | 200 | 0.7547 |
| 11:34 ET | 2467 | 0.745802 |
| 11:36 ET | 405 | 0.7541 |
| 11:39 ET | 500 | 0.7541 |
| 11:41 ET | 100 | 0.7541 |
| 11:43 ET | 1329 | 0.7541 |
| 11:45 ET | 700 | 0.7541 |
| 11:48 ET | 799 | 0.7541 |
| 11:50 ET | 300 | 0.7541 |
| 11:52 ET | 300 | 0.7541 |
| 11:56 ET | 1200 | 0.7541 |
| 11:57 ET | 600 | 0.7541 |
| 11:59 ET | 600 | 0.7541 |
| 12:01 ET | 600 | 0.7541 |
| 12:03 ET | 659 | 0.7547 |
| 12:06 ET | 4319 | 0.76 |
| 12:08 ET | 7657 | 0.76 |
| 12:10 ET | 6511 | 0.76 |
| 12:12 ET | 2000 | 0.761 |
| 12:14 ET | 7423 | 0.75785 |
| 12:15 ET | 1300 | 0.775 |
| 12:17 ET | 4870 | 0.7737 |
| 12:21 ET | 1900 | 0.755 |
| 12:24 ET | 5163 | 0.7547 |
| 12:26 ET | 7785 | 0.775 |
| 12:28 ET | 4358 | 0.75 |
| 12:30 ET | 21131 | 0.75 |
| 12:32 ET | 300 | 0.7495 |
| 12:33 ET | 100 | 0.7601 |
| 12:35 ET | 5186 | 0.7696 |
| 12:37 ET | 3000 | 0.7598 |
| 12:39 ET | 5565 | 0.7598 |
| 12:44 ET | 200 | 0.76 |
| 12:48 ET | 200 | 0.7586 |
| 12:50 ET | 400 | 0.7598 |
| 12:53 ET | 3926 | 0.75 |
| 12:55 ET | 4795 | 0.7532 |
| 12:57 ET | 5537 | 0.7545 |
| 01:00 ET | 26273 | 0.7564 |
Nov 4, 2024
Renovaro Issues Shareholder Letter and Provides Corporate Update, from 8:31AM ET on Monday Nov 04, 2024 by Dow Jones
8:31AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Renovaro Inc | 96.9M | -0.8x | --- |
Hillevax Inc | 95.1M | -0.6x | --- |
Tiziana Life Sciences Ltd | 101.8M | -5.5x | --- |
Genelux Corp | 92.9M | -2.8x | --- |
Nuvectis Pharma Inc | 102.0M | -4.3x | --- |
Adicet Bio Inc | 91.5M | -0.7x | --- |
Company Information
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Contact Information
- Headquarters
- Century City Medical Plaza 2080 Century City East, Suite 906LOS ANGELES, CA, United States 90067
- Phone
- 212-763-0184
- Fax
- 845-818-3588
Executives
- Independent Chairman of the Board
- Maurice van Tilburg
- Chief Executive Officer, Director
- David Weinstein
- Interim Chief Financial Officer
- Simon Tarsh
- Chief Operating Officer
- Francois Binette
- Independent Director
- Douglas Calder
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $96.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 158.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.65 |
EPS | $-0.93 |
Book Value | $0.85 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
